Karyopharm Therapeutics Inc. (KPTI) Reaches $14.74 After 7.00% Up Move; Core-mark Holding Company (CORE) Shorts Increased By 19.23%

April 17, 2018 - By wolcottdaily

Core-Mark Holding Company, Inc. (NASDAQ:CORE) Logo

The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a huge mover today! The stock increased 4.91% or $0.69 during the last trading session, reaching $14.74. About 161,171 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since April 17, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.The move comes after 5 months positive chart setup for the $731.88M company. It was reported on Apr, 17 by Barchart.com. We have $15.77 PT which if reached, will make NASDAQ:KPTI worth $51.23M more.

Core-mark Holding Company Inc (NASDAQ:CORE) had an increase of 19.23% in short interest. CORE’s SI was 2.08M shares in April as released by FINRA. Its up 19.23% from 1.75 million shares previously. With 337,000 avg volume, 6 days are for Core-mark Holding Company Inc (NASDAQ:CORE)’s short sellers to cover CORE’s short positions. The SI to Core-mark Holding Company Inc’s float is 4.63%. The stock increased 1.90% or $0.41 during the last trading session, reaching $21.99. About 55,419 shares traded. Core-Mark Holding Company, Inc. (NASDAQ:CORE) has declined 32.34% since April 17, 2017 and is downtrending. It has underperformed by 43.89% the S&P500.

Since December 11, 2017, it had 0 insider buys, and 23 selling transactions for $2.49 million activity. Shacham Sharon had sold 10,000 shares worth $100,769 on Monday, January 8. Kauffman Michael sold $161,463 worth of stock. Mirza Mansoor Raza had sold 1,500 shares worth $19,500 on Wednesday, February 7. Primiano Christopher Brett sold $19,500 worth of stock.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 34 analyst reports since August 11, 2015 according to SRatingsIntel. Bank of America downgraded Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Tuesday, March 15. Bank of America has “Underperform” rating and $11 target. Raymond James initiated the shares of KPTI in report on Friday, May 27 with “Outperform” rating. Cantor Fitzgerald maintained the shares of KPTI in report on Friday, June 23 with “Buy” rating. Robert W. Baird maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Thursday, March 15 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Thursday, January 11. Jefferies initiated it with “Buy” rating and $23 target in Wednesday, September 9 report. Canaccord Genuity maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Tuesday, August 8. Canaccord Genuity has “Buy” rating and $1800 target. JP Morgan maintained the shares of KPTI in report on Monday, March 14 with “Overweight” rating. Jefferies maintained the stock with “Buy” rating in Monday, September 11 report. Canaccord Genuity maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Monday, March 12. Canaccord Genuity has “Buy” rating and $22 target.

Investors sentiment decreased to 1.56 in 2017 Q4. Its down 0.94, from 2.5 in 2017Q3. It turned negative, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. Sandy Spring National Bank & Trust stated it has 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Wellington Ltd Liability Partnership holds 0.01% or 6.04 million shares. Tower Research Capital Limited Liability Company (Trc) holds 893 shares. Northern Trust has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Geode Cap Management Limited Liability Company, Massachusetts-based fund reported 280,610 shares. 56,850 were accumulated by Swiss Natl Bank. Deutsche Comml Bank Ag reported 188,373 shares. Tudor Invest Et Al owns 0.01% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 22,836 shares. 19,130 were reported by Prudential Inc. Parallax Volatility Advisers L P holds 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 5,124 shares. Moreover, First Personal Finance Ser has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 1,187 shares. Royal Bank Of Canada owns 714 shares for 0% of their portfolio. State Street reported 589,786 shares. Proshare Advisors Ltd Liability accumulated 30,437 shares. Manufacturers Life Ins Company The, a Ontario – Canada-based fund reported 26,729 shares.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $731.88 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on May, 3. They expect $-0.67 earnings per share, up 5.63% or $0.04 from last year’s $-0.71 per share. After $-0.80 actual earnings per share reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -16.25% EPS growth.

Among 8 analysts covering Core-Mark Holding Company (NASDAQ:CORE), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Core-Mark Holding Company had 24 analyst reports since August 7, 2015 according to SRatingsIntel. The company was upgraded on Friday, January 5 by Raymond James. Jefferies maintained Core-Mark Holding Company, Inc. (NASDAQ:CORE) rating on Thursday, October 12. Jefferies has “Hold” rating and $34.0 target. The stock has “Hold” rating by Jefferies on Wednesday, June 21. As per Friday, January 5, the company rating was downgraded by Stephens. The rating was maintained by Raymond James with “Outperform” on Tuesday, August 30. Raymond James maintained Core-Mark Holding Company, Inc. (NASDAQ:CORE) rating on Wednesday, August 9. Raymond James has “Outperform” rating and $35 target. Stephens maintained Core-Mark Holding Company, Inc. (NASDAQ:CORE) on Wednesday, October 28 with “Overweight” rating. The stock has “Hold” rating by Jefferies on Monday, January 29. Jefferies maintained the shares of CORE in report on Thursday, August 3 with “Hold” rating. On Thursday, March 1 the stock rating was maintained by Jefferies with “Hold”.

Investors sentiment decreased to 1.12 in Q4 2017. Its down 0.04, from 1.16 in 2017Q3. It dropped, as 10 investors sold Core-Mark Holding Company, Inc. shares while 49 reduced holdings. 22 funds opened positions while 44 raised stakes. 41.59 million shares or 3.92% less from 43.28 million shares in 2017Q3 were reported. Glenmede Trust Na holds 0% of its portfolio in Core-Mark Holding Company, Inc. (NASDAQ:CORE) for 1,716 shares. Tiaa Cref Invest Management Lc reported 172,794 shares. 18,775 are held by Bw Gestao De Investimentos Ltda. State Of Wisconsin Inv Board, Wisconsin-based fund reported 378,200 shares. Eulav Asset Mgmt, New York-based fund reported 42,700 shares. Tower Research Capital Ltd Liability Co (Trc) holds 374 shares or 0% of its portfolio. Guggenheim Cap Limited Liability has 0% invested in Core-Mark Holding Company, Inc. (NASDAQ:CORE). Aqr Capital Ltd has invested 0% of its portfolio in Core-Mark Holding Company, Inc. (NASDAQ:CORE). Frontier Management Ltd Limited Liability Company invested 0.04% of its portfolio in Core-Mark Holding Company, Inc. (NASDAQ:CORE). Federated Investors Pa invested in 48 shares or 0% of the stock. Zebra Cap Management Lc owns 22,851 shares or 0.24% of their US portfolio. Citigroup accumulated 11,700 shares or 0% of the stock. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,665 shares. State Of New Jersey Common Pension Fund D accumulated 840,000 shares or 0.1% of the stock. First Tru Advsrs Lp invested in 10,818 shares or 0% of the stock.

Since March 14, 2018, it had 0 insider buys, and 1 sale for $145,598 activity. On Wednesday, March 14 the insider Rolheiser Eric sold $145,598.

Core-Mark Holding Company, Inc. markets fresh and broad-line supply solutions to the convenience retail industry. The company has market cap of $1.02 billion. The firm sells and distributes various food/non-food products, including cigarettes, fast food, candies, snacks, groceries, fresh products, dairy products, breads, beverages, other tobacco products, general merchandise and equipment, and health and beauty care products. It has a 30.54 P/E ratio. The Company’s clients include traditional convenience stores, such as national and super-regional convenience store operators, as well as independently owned convenience stores; and alternative outlets, which include grocery stores, drug stores, liquor stores, cigarette and tobacco shops, hotel gift shops, military exchanges, college and corporate campuses, casinos, hardware stores, airport concessions, and other specialty and small format stores that carry convenience products.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 wolcottdaily

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: